Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain

Arthritis and Rheumatism

Volumn 54, Issue 8, 2006, Pages 2656-2664

  Üçeyler, Nurcan ^a,b   Valenza, Regine ^a   Stock, Michael ^a   Schedel, Robert ^a   Sprotte, Günter ^a   Sommer, Claudia ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 8; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROMYALGIA; GENE EXPRESSION; HUMAN; INFLAMMATION; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TH2 CELL;

ADULT; AGED; CHRONIC DISEASE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33747006154     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22026     Document Type: Article

References (50)

1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72.
3. Wallace DJ, Margolin K, Waller P. Fibromyalgia and interleukin-2 therapy for malignancy [letter]. Ann Intern Med 1988;108:909.
4. Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003;23:2517-21.
5. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004;361:184-7.
6. Goebel A, Netal S, Schedel R, Sprotte G. Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med 2002;3:119-27.
7. Kruse N, Pette M, Toyka K, Rieckmann P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Methods 1997;210:195-203.
8. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-601.
9. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 1997;24:555-9.
10. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993;20:469-74.
11. Mense S. Neurobiological concepts of fibromyalgia: the possible role of descending spinal tracts. Scand J Rheumatol Suppl 2000;113:24-9.
12. Staud R, Price DD, Robinson ME, Mauderli AP, Vierck CJ. Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared to normal controls. Pain 2004;110:689-96.
13. Buskila D, Neumann L, Hazanov I, Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 1996;26:605-11.
14. Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah S. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999;26:408-12.
15. Bondy B, Spaeth M, Offenbaecher M, Glatzeder K, Stratz T, Schwarz M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999;6:433-9.
16. Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits [letter]. Arthritis Rheum 2002;46:845-7.
17. Hartung HP, Wolters K, Toyka KV. Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol 1986;136:3856-63.
18. Hader N, Rimon D, Kinarty A, Lahat N. Altered interleukin-2 secretion in patients with primary fibromyalgia syndrome. Arthritis Rheum 1991;34:866-72.
19. Gur A, Karakoc M, Nas K, Cevik R, Denli A, Sarac J. Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002;29:358-61.
20. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001;40:743-9.
21. Amel Kashipaz MR, Swinden D, Todd I, Powell RJ. Normal production of inflammatory cytokines in chronic fatigue and fibromyalgia syndromes determined by intracellular cytokine staining in short-term cultured blood mononuclear cells. Clin Exp Immunol 2003;132:360-5.
22. Salemi S, Aeschlimann A, Gay RE, Michel BA, Gay S, Kaeser L, et al. Expression and localization of opioid receptors in muscle satellite cells: no difference between fibromyalgia patients and healthy subjects. Arthritis Rheum 2003;48:3291-3.
23. Eriksson P, Andersson C, Ekerfelt C, Ernerudh J, Skogh T. Sjogren's syndrome with myalgia is associated with subnormal secretion of cytokines by peripheral blood mononuclear cells. J Rheumatol 2004;31:729-35.
24. Ding YZ, Fu S, Zamarin D, Bromberg J. Interleukin 10. In: Thomson AW, Lotze MT, editors. The cytokine handbook. Vol. 1. 4th ed. London: Academic Press; 2003. p. 603-25.
25. Kleinschnitz C, Brinkhoff J, Sommer C, Stoll G. Contralateral cytokine gene induction after peripheral nerve lesions: dependence on the mode of injury and NMDA receptor signaling. Brain Res Mol Brain Res 2005;136:23-8.
26. George A, Kleinschnitz C, Zelenka M, Brinkhoff J, Stoll G, Sommer C. Wallerian degeneration after crush or chronic constriction injury of rodent sciatic nerve is associated with a depletion of endoneurial interleukin-10 protein. Exp Neurol 2004;188:187-91.
27. George A, Marziniak M, Schafers M, Toyka KV, Sommer C, Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-α, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 2000;88:267-75.
28. Kleinschnitz C, Brinkhoff J, Zelenka M, Sommer C, Stoll G. The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol 2004;149:77-83.
29. Vale ML, Marques JB, Moreira CA, Rocha FA, Ferreira SH, Poole S, et al. Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. J Pharmacol Exp Ther 2003;304:102-8.
30. Kanaan SA, Poole S, Saade NE, Jabbur S, Safieh-Garabedian B. Interleukin-10 reduces the endotoxin-induced hyperalgesia in mice. J Neuroimmunol 1998;86:142-50.
31. Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J, O'Connor K, et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 2005;21:2136-48.
32. Okada H, Banchereau J, Lotze MT. Interleukin 4. In: Thomson AW, Lotze MT, editors. The cytokine handbook. Vol. 1. 4th ed. London: Academic Press; 2003. p. 227-62.
33. Hao S, Mata M, Glorioso JC, Fink DJ. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain [serial online]. 2006;2(6). URL http://www.pubmedcentral.gov/articlerender. fcgi?tool=pubmed&pubmedid=16503976.
34. Kraus J, Borner C, Giannini E, Hickfang K, Braun H, Mayer P, et al. Regulation of μ-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 2001;276:43901-8.
35. Borner C, Woltje M, Hollt V, Kraus J. STAT6 transcription factor binding sites with mismatches within the canonical 5′-TTC. GAA-3′ motif involved in regulation of δ- and μ-opioid receptors. J Neurochem 2004;91:1493-500.
36. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M. Association between -G308A tumor necrosis factor α gene polymorphism and schizophrenia. Mol Psychiatry 2001;6:79-82.
37. Hobbs K, Negri J, Klinnert M, Rosenwasser LJ, Borish L. Interleukin-10 and transforming growth factor-β promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med 1998;158:1958-62.
38. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Nickerson P, et al. Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1115-21.
39. Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kawashima T, et al. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy 1998;28:449-53.
40. Klein W, Tromm A, Griga T, Fricke H, Folwaczny C, Hocke M, et al. Interleukin-4 and interleukin-4 receptor gene polymorphisms in inflammatory bowel diseases. Genes Immun 2001;2:287-9.
41. Buchs N, Silvestri T, di Giovine FS, Chabaud M, Vannier E, Duff GW, et al. IL-4 VNTR gene polymorphism in chronic polyarthritis: the rare allele is associated with protection against destruction. Rheumatology (Oxford) 2000;39:1126-31.
42. Roy S, Wang J, Gupta S, Charboneau R, Loh HH, Barke RA. Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T-bet. J Neuroimmunol 2004;147:78-81.
43. Aukrust P, Muller F, Svenson M, Nordoy I, Bendtzen K, Froland SS. Administration of intravenous immunoglobulin (IVIG) in vivo-down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999;115:136-43.
44. Gonzalez H, Khademi M, Andersson M, Piehl F, Wallstrom E, Borg K, et al. Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 2004;150:139-44.
45. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201-17.
46. Miller DB, O'Callaghan JP. Depression, cytokines, and glial function. Metabolism 2005;54(5 Suppl 1):33-8.
47. Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry 1994;35:42-7.
48. Kubera M, Kenis G, Bosmans E, Jaworska-Feil L, Lason W, Scharpe S, et al. Suppressive effect of TRH and imipramine on human interferon-γ and interleukin-10 production in vitro. Pol J Pharmacol 2000;52:481-6.
49. Pedersen BK, Ostrowski K, Rohde T, Bruunsgaard H. The cytokine response to strenuous exercise. Can J Physiol Pharmacol 1998;76:505-11.
50. Kovacs EJ, Messingham KA. Influence of alcohol and gender on immune response. Alcohol Res Health 2002;26:257-63.